Discover how 180-day exclusivity works under the Hatch-Waxman Act, impacting generic drug entry and patent challenges.
Complex generic drugs face unique scientific and regulatory hurdles that make FDA approval far harder than for simple generics. From liposomal injections to inhalers, these drugs require advanced testing, costly development, and evolving guidelines-delaying affordable access for patients.
